Metis Global Partners LLC Lowers Holdings in Agilent Technologies, Inc. $A

Metis Global Partners LLC trimmed its holdings in Agilent Technologies, Inc. (NYSE:A) by 6.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,600 shares of the medical research company’s stock after selling 1,108 shares during the quarter. Metis Global Partners LLC’s holdings in Agilent Technologies were worth $1,959,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of A. Generation Investment Management LLP lifted its holdings in shares of Agilent Technologies by 19.8% in the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock worth $582,976,000 after buying an additional 824,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Agilent Technologies by 18.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock valued at $448,748,000 after acquiring an additional 604,124 shares during the last quarter. Mackenzie Financial Corp lifted its stake in Agilent Technologies by 141.5% in the 1st quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock worth $109,481,000 after purchasing an additional 548,344 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of Agilent Technologies by 681.6% during the 1st quarter. Woodline Partners LP now owns 522,073 shares of the medical research company’s stock valued at $61,072,000 after purchasing an additional 455,276 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Agilent Technologies by 16.2% during the second quarter. Nordea Investment Management AB now owns 3,213,748 shares of the medical research company’s stock valued at $383,143,000 after purchasing an additional 447,207 shares in the last quarter. Institutional investors own 87.41% of the company’s stock.

Analyst Upgrades and Downgrades

A has been the topic of a number of research analyst reports. Robert W. Baird boosted their target price on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. Evercore ISI upped their price objective on Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a report on Tuesday, October 7th. Barclays raised their target price on shares of Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Rothschild Redb raised shares of Agilent Technologies to a “strong-buy” rating in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $149.62.

Agilent Technologies Stock Down 0.5%

NYSE A opened at $146.69 on Monday. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53. The company has a fifty day moving average of $135.48 and a two-hundred day moving average of $122.56. The firm has a market capitalization of $41.59 billion, a price-to-earnings ratio of 34.43, a PEG ratio of 4.67 and a beta of 1.29. Agilent Technologies, Inc. has a 52 week low of $96.43 and a 52 week high of $153.84.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same quarter in the prior year, the firm posted $1.32 earnings per share. The business’s revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th were paid a $0.248 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $0.99 annualized dividend and a yield of 0.7%. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.24%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.